A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
about
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataIdelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyIbrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisThe Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network PerspectiveTargeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyManagement of elderly and unfit patients with chronic lymphocytic leukemia.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Richter transformation of CLL.An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessIdelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomasIdelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.Chronic lymphocytic leukemia therapy: new targeted therapies on the wayIdelalisib for the treatment of non-Hodgkin lymphoma.A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.PI3Kδ and primary immunodeficiencies.Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.Chronic lymphocytic leukemia (CLL)-Then and now.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.The molecular pathogenesis of chronic lymphocytic leukaemia.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.Idelalisib and Rituximab Regimen.Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.Recent advances in therapy of chronic lymphocytic leukaemia.Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.Current Treatment of Chronic Lymphocytic Leukemia.Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.Advances in the treatment of relapsed/refractory chronic lymphocytic leukemiaOutcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
P2860
Q26738934-40348A33-118E-404C-87CA-906B9F4FD622Q26747753-0F398E19-B7C3-4A40-8207-62199288859BQ26765624-603A8CB8-263A-45CD-86C5-3ACAB5205178Q28080304-B96A321D-D517-4F12-87B9-A7960193654AQ28277551-1D7CD4D7-9035-43E9-8F06-64938BC25165Q28553277-F0B09027-C900-41D7-94AA-DABD57C02F94Q29248893-B94E14D3-F2EC-4F1A-9643-17894D0689F3Q30243914-1FCDB355-F42D-46AD-A820-16783CE54091Q30243968-C4F1C5D9-CFFF-467A-9874-01538B07FAA1Q30249283-B36BFB03-F569-40B0-9B7C-23620A73A85DQ33709543-09E9501C-A5F1-442B-A679-E5683BB41169Q37058203-934A54CF-DBD6-4DCB-9548-EE33D6E7E442Q37097096-18E6910D-B2B5-4FBB-BC0D-CD19BBDBFB85Q37113544-F88D0679-045D-439B-9DBB-A76C91A3BAD5Q37114445-26D8930C-8C76-4ECC-B2F4-E03714DCF825Q37321917-41D89B3D-E1FE-4F93-BA2D-AA1F6D8984FBQ37429218-F649F884-B423-4CAC-8E7A-CAF497E101E0Q37623828-9101AA26-80F7-453B-8CAA-3BB34F6DFB76Q37701548-8E637004-01F4-46F0-96CE-35EA81ED1B0BQ37725415-9DB54FC0-8730-4947-9BFF-EA3372F7FAFAQ38675358-BB9665E5-7EB4-4961-874F-110A8CC10B1BQ38691282-6F22DB7C-707F-468C-A131-7791513E0503Q38738661-B748E10C-FDEF-4D6F-B87E-406A57EA638AQ38748645-A87B46A6-3FF9-49A4-91CA-F5549DFCED0AQ38807514-9E39B26F-6440-40B6-8E77-8B5C0673AB9DQ38821937-B1EB6723-AAC7-4811-9AFB-98FA7C959674Q38850667-5B8803AB-24F3-45E9-ACFE-914EF97049D7Q38851368-F4231946-7F1F-4795-A1C3-19F30C2FD650Q38858806-4016D5F1-B573-4C16-AF98-59A3D336FFD7Q38862525-A3224796-1DC7-421B-8ABD-590E52143B76Q38897083-A7B05F2C-D72F-46D4-80B0-9C0B0ECA4A8DQ38943877-5871F15B-6BB1-4B5C-BDD1-8C36E7D1EDD3Q39018189-C31C6F02-1061-4F86-8D7F-3C43D0047C17Q39034465-D62E39D4-A379-44D0-9799-5B696AB86CBCQ39129372-469F5714-380D-4180-B1A1-D33B566C7B77Q39226787-7D4EEE96-A62C-487E-A460-83110DB1E84DQ39227773-35E1B306-A688-4F36-B424-767E1953479EQ39763635-ED6D34D6-8A85-4D2C-9F3F-4D475ECFC663Q40394474-C9F4E545-5D61-46D6-A1B7-C81BE668E371Q41994564-FE508AE6-C1B2-4E19-8E18-DD55B0A2D38E
P2860
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.
@ast
A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.
@en
type
label
A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.
@ast
A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.
@en
prefLabel
A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.
@ast
A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P1433
P1476
A phase 2 study of idelalisib ...... chronic lymphocytic leukemia.
@en
P2093
Albert S Yu
Andrew D Zelenetz
David M Johnson
Jan A Burger
Langdon L Miller
Leanne Holes
Nicole Lamanna
Roger D Dansey
Ronald L Dubowy
P2860
P304
P356
10.1182/BLOOD-2015-03-630947
P407
P577
2015-10-15T00:00:00Z